University of Chicago
Otolaryngology residency · Chicago, IL · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is University of Chicago's research in otolaryngology, which the program shares with other departments and affiliated hospitals.
About University of Chicagoinstitution-wide otolaryngology research
Otolaryngology publications from University of Chicago and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
23
works per year
12th of 56 otolaryngology residency programs
+25.0%
2-year growth
17th of 54 otolaryngology residency programs
25.9%
in top 10% of field (works before 2025)
23rd of 39 otolaryngology residency programs
46.6%
cited above world average
30th of 39 otolaryngology residency programs
Works per year · * 2026 so far
Otorhinolaryngology · 111
Otolaryngology research topics at University of Chicago
Papers in the window; each links to the list on OpenAlex.
Most cited at University of Chicago since 2024
All otolaryngology papers there on OpenAlex
- Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV + Oropharyngeal CancerAri Joseph Rosenberg et al. · JAMA Oncology · 2024 · PubMed · cited 60
- Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck CancerAri Joseph Rosenberg et al. · JAMA Oncology · 2025 · PubMed · cited 36
- Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck CancerPaul Loren Swiecicki et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 32
- Air pollution, genetic factors, and chronic rhinosinusitis: A prospective study in the UK BiobankQinfeng Zhou et al. · The Science of The Total Environment · 2024 · PubMed · cited 29
- Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 ImmunotherapyAri Joseph Rosenberg et al. · American Society of Clinical Oncology Educational Book · 2024 · PubMed · cited 20
- LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCCJean‐Pascal Machiels et al. · Future Oncology · 2025 · PubMed · cited 18
- Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancerThomas F. Cyberski et al. · npj Precision Oncology · 2024 · PubMed · cited 17
- The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polypsAnju Tripathi Peters et al. · Allergy and Asthma Proceedings · 2025 · PubMed · cited 14
- Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 studyKevin Joseph Harrington et al. · Oral Oncology · 2025 · PubMed · cited 13
- A Multi‐Center Study of Ossiculoplasty Hearing Outcomes and a Grading Scale of Ear Environment RiskMichael Brian Gluth et al. · The Laryngoscope · 2024 · PubMed · cited 13